Physician profile
Joanne E Tsai
NPI 1346260148
$1,329.50
in general payments reported to CMS, 2019-2025
12 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.64 · 2020: $102 · 2022: $200 · 2023: $65.68 · 2024: $446 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $305.48 | 2022-2024 | Micra, Cobalt Dr Mri Surescan |
| Abiomed | $217.76 | 2024-2025 | Impella |
| Medtronic Vascular, INC. | $144.92 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $141.09 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $121.23 | 2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $89.02 | 2024-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $86.24 | 2024-2025 | Wainua, Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $76.17 | 2024 | Arcalyst |
| Amgen INC. | $57.66 | 2024-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $38.12 | 2024-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $29.14 | 2025 | Capvaxive, Verquvo |
| Bolton Medical INC | $22.67 | 2024 | Treo Abdominal Stent-Graft System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.